Aurobindo Pharma Limited (AUROPHARMA) — FY26 Annual Report | 29 July 2026

· NSE 🔴 High Importance Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
📢 Key Event
39th AGM scheduled for August 27, 2026
💡 Investor Takeaway
Shareholders must register their email IDs to receive meeting notices and report access details.

Aurobindo Pharma announced its 39th Annual General Meeting scheduled for August 27, 2026, via video conference, with the integrated annual report for FY25-26 to be distributed to shareholders and posted on its website.

📄 View Original Announcement (PDF)

About Aurobindo Pharma Limited (AUROPHARMA)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹87,805.59 Cr P/E: 25.3

View full AUROPHARMA stock details →

📡 Get AI alerts when AUROPHARMA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track AUROPHARMA — Free

📊 More AUROPHARMA filings

See all AUROPHARMA filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when AUROPHARMA files new disclosures

Track AUROPHARMA filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track AUROPHARMA — Free

Free account · 2 AI queries/day